 price
pharmexit boost impact improv
put solid start larg
strength oper result given continu
improv industri fundament saw last quarter
well elimin pharmedium drag
ep estim broadli revis chang
stem pharmedium estim
street prior quarter turn year
forecast modest gross margin pressur moder
opex manag one potenti swing factor
street estim model manag use
higher cash balanc overal estim revis
caus us rais pt though valuat continu
impair opioid overhang thu reiter
line rate
pleas see confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
face challeng expect despit progress remedi
busi sellabl larg due regulatori hurdl
chang made difficult scale busi
primari driver decis close oper
expect claim tax deduct realiz cash tax benefit mm
pharmedium decis suspend product nj facil catalyst abc decis
expect materi hurt specialti relationship hospit
ep growth low-end rang management expect higher oper expens compar
slightli less half ep guidanc rang increas pharmedium exit
favor comp respect quarter
mm tailwind pharmedium exit
continu toward global resolut also prepar upcom trial
pharmaceut distribut benefit specialti distribut custom growth
specialti physician servic group benefit favor bad debt expens longer
increas pharmaceut innov specialti area continu drive growth
posit anim health mwi outlook strong
reiter commit invest busi organ return cash sharehold
follow histor model repo dividend
would consid right acquisit though call current time seller market
comment
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti resumpt independ price war result materi margin degrad
signific profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin
result overal compress increment soft pharmedium growth lessen inflat continu challeng
relat revamp qc process polit threat chang rx price methodolog gross net intens scrutini
opioid curtail distribut profit execut challeng onboard hd smith asset potenti leakag key
independ custom transit period inabl transit specialti contract long term new econom
allow fair payment differenti servic
articl articl
time dissemin januari
analyst elizabeth anderson suzi yoon amato primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
